Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.28 billion, representing a surprise of -7.53%. The company delivered an EPS surprise of -2.49%, with the consensus EPS estimate being $8.43.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Regeneron performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Praluent (alirocumab)- US: $56.80 million versus $57.71 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -18.9% change.
- Revenues- Eylea (Aflibercept)- US: $1.04 billion versus $1.19 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -25.6% change.
- Revenues- Evkeeza- US: $31 million versus $32.40 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +29.2% change.
- Revenues- Libtayo- US: $192.50 million versus the three-analyst average estimate of $214.99 million. The reported number represents a year-over-year change of +20.9%.
- Revenues- Other Revenue: $81.90 million versus the six-analyst average estimate of $132.13 million. The reported number represents a year-over-year change of -29.9%.
- Revenues- Net product sales: $1.42 billion versus $1.62 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -19.6% change.
- Total Bayer collaboration revenue: $343.90 million versus the five-analyst average estimate of $374.73 million. The reported number represents a year-over-year change of -3.4%.
- Revenues- Collaboration: $1.53 billion compared to the $1.49 billion average estimate based on five analysts. The reported number represents a change of +20.9% year over year.
- Total Sanofi collaboration revenue: $1.18 billion compared to the $1.12 billion average estimate based on five analysts. The reported number represents a change of +30% year over year.
- Revenues- Libtayo- Total: $285.10 million versus the four-analyst average estimate of $346.20 million. The reported number represents a year-over-year change of +8%.
- Revenues- Praluent (alirocumab)- Total: $193.30 million compared to the $203.86 million average estimate based on two analysts. The reported number represents a change of -4% year over year.
- Revenues- Kevzara (sarilumab)- Total: $116.40 million versus $94.41 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +23.7% change.
View all Key Company Metrics for Regeneron here>>>
Shares of Regeneron have returned -3.7% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
